Skip to main content

Press Release


IK Investment Partners acquires KLINGEL medical metal

Press Releases

IK Investment Partners (“IK”) is pleased to announce that the IK VIII Fund has reached an agreement to acquire Klingel medical metal GmbH (“KLINGEL” or “the Company”), a leading manufacturer of high-precision and complex metal components mainly for a range of medical technology applications, from Halder.

KLINGEL was established in 1986 and has become a leading independent contract manufacturer of high-precision, hard-to-machine parts made from titanium and high-grade types of stainless steel. The Company operates a vertically integrated business model with in-house capabilities spanning the entire production value chain from design to manufacture to final packaging with a strategic focus on medical technology. KLINGEL’s high precision components go into various orthopaedic, cardiovascular and dental implants as well as instruments for endoscopy and robotic surgery.

Working in partnership with its OEM customers across the medical technology as well as measurement and control industries, KLINGEL has gained a reputation for uncompromising quality. Headquartered in Pforzheim, Germany, the Company operates two manufacturing sites with over 200 CNC machines and employs more than 300 people.

“By providing mission critical components of the highest quality standards, KLINGEL has formed long-standing relationships with our customers. IK has a genuine understanding of the CMO market and shares our international growth strategy. With their support, we will continue contributing to our customers’ success by offering real added value to their end consumers,” said Ralf Petrawitz, Technical and Commercial Managing Director of KLINGEL.

“We are impressed by KLINGEL’s strong management team. Together we will continue to build on the strong market position, technical know-how and broad service offering KLINGEL has developed over the last three decades. IK is well-positioned to support KLINGEL thanks to our experience with Marle, a leading European CMO of hip and knee orthopaedic implants, acquired in 2016,” says Anders Petersson, Partner at IK.

KLINGEL represents the IK VIII Fund’s second mid cap acquisition in the past month, and the 11th acquisition announced by the Fund. Financial terms of the transaction are not disclosed.

Parties involved:
IK Investment Partners: Anders Petersson, Mirko Jablonsky, Alexander Dokters, Adrian Tanski, Daniel-Vito Günther
Buyer financial advisor: Quarton International (Lars Veit, Rolf Holtmann)
Buyer strategic due diligence: Alvarez & Marsal (Georg Hochleitner)
Buyer financial due diligence: Ebner Stolz (Claus Bähre)
Buyer legal advisor: Renzenbrink & Partner (Ulf Renzenbrink)
Halder: Michael Wahl, Christian Muschalik
Seller financial advisor: William Blair (Philipp Mohr, Moritz Rottwinkel)
Seller legal advisor: Graf von Westfalen (Lutz Zimmer, Ernst Lindl)

For further questions, please contact:

KLINGEL medical metal
Ralf Petrawitz, Managing Director
Phone: +49 7231 6519 0

IK Investment Partners
Anders Petersson, Partner
Phone: +49 40 369 8850

Mikaela Hedborg, Director Communications & ESG
Phone: +44 77 87 573 566

About IK Investment Partners

IK Investment Partners (“IK”) is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised more than €9.5 billion of capital and invested in over 115 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit

About KLINGEL medical metal

For more than 30 years, KLINGEL medical metal GmbH has been one of the leading European precision technology companies with a strategic focus on medical technology industries. Employing over 300 people, KLINGEL medical metal GmbH specialises in the precision processing of materials with low machinability, such as titanium and high-grade stainless steel. KLINGEL offers unrivalled technical quality and aesthetic perfection. For more information, visit

Recent News

IK Partners to invest in BIOBank alongside Management and historical shareholders Verto Growth and Capital Croissance
Read More
IK Partners divests Yellow Hive to a newly established continuation fund
Read More
Stake in A-SAFE acquired by IK Partners
Read More